Compass Therapeutics, Inc. - 10-Q Filing
Compass Therapeutics reports Q3 2026 financial results including research and development expense breakdowns across CTX programs.
Tickers: $CMPX
Compass Therapeutics reports Q3 2026 financial results including research and development expense breakdowns across CTX programs.
Tickers: $CMPX